COVID-19 outcomes in patients with multiple sclerosis: understanding changes from 2020 to 2022 - Sorbonne Université Access content directly
Journal Articles Multiple Sclerosis Journal Year : 2024

COVID-19 outcomes in patients with multiple sclerosis: understanding changes from 2020 to 2022

Jérôme de Seze
  • Function : Author
Hélène Zéphir
  • Function : Author
Jean Pelletier
  • Function : Author
Philippe Kerschen
  • Function : Author
Olivier Heinzlef
  • Function : Author
Laurent Guilloton
  • Function : Author
Olivier Casez
  • Function : Author
Aude Maurousset
  • Function : Author
David Laplaud
  • Function : Author
Eric Berger
  • Function : Author
Christine Lebrun-Frenay
  • Function : Author
Bertrand Bourre
  • Function : Author
Eric Thouvenot
Eric Manchon
  • Function : Author
Thibault Moreau
  • Function : Author

Abstract

Background: Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021. Objectives: We aimed to extend these data from the onset of the pandemic to the global coverage by vaccination in summer 2022. Methods: This retrospective, multicenter observational study analyzed COVISEP registry data on reported COVID-19 cases in pwMS between January 2020 and July 2022. Severe COVID-19 was defined as hospitalization or higher severity. Results: Among 2584 pwMS with confirmed/highly suspected COVID-19, severe infection rates declined from 14.6% preomicron wave to 5.7% during omicron wave ( p < 0.001). Multivariate analysis identified age (odds ratio (OR) = 1.43, 95% confidence interval (CI) = [1.25–1.64] per 10 years), male sex (OR = 2.01, 95% CI = [1.51–2.67]), obesity (OR = 2.36, 95% CI = [1.52–3.68]), cardiac comorbidities (OR = 2.36, 95% CI = [1.46–3.83]), higher Expanded Disability Status Scale (EDSS) scores (OR = 2.09, 95% CI = [1.43–3.06] for EDSS 3–5.5 and OR = 4.53, 95% CI = [3.04–6.75] for EDSS ⩾6), and anti-CD20 therapies (OR = 2.67, 95% CI = [1.85–3.87]) as risk factors for COVID-19 severity. Vaccinated individuals experienced less severe COVID-19, whether on (risk ratio (RR) = 0.64, 95% CI = [0.60–0.69]) or off (RR = 0.32, 95% CI = [0.30–0.33]) anti-CD20. Discussion: In pwMS, consistent risk factors were anti-CD20 therapies and neurological disability, emerging as vital drivers of COVID-19 severity regardless of wave, period, or vaccination status.
Fichier principal
Vignette du fichier
covisep_hal.pdf (931.88 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-04413759 , version 1 (24-01-2024)

Identifiers

Cite

Lina Jeantin, Edouard Januel, Pierre Labauge, Elisabeth Maillart, Jérôme de Seze, et al.. COVID-19 outcomes in patients with multiple sclerosis: understanding changes from 2020 to 2022. Multiple Sclerosis Journal, 2024, ⟨10.1177/13524585231218149⟩. ⟨hal-04413759⟩
32 View
33 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More